A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Leukemia
9 protocols meet the specified criteria.
-
-
A211901
Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions -
CCTL019B2003I
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release -
COG-AALL1621
AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) -
EAY191
Molecular Analysis for Combination Therapy Choice (ComboMATCH) -
GRAIL-MA-002
REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study) -
JCAR017-EAP-001
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release -
KT-US-472-0141
Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication -
WVU010922
Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia